Ketamine for OCD: Rapid Relief, Short Duration in Clinical Review

Ketamine Produces Rapid, Temporary Symptom Relief in OCD

Intravenous ketamine at subanesthetic doses can induce a rapid and clinically significant reduction in obsessive-compulsive disorder (OCD) symptoms, according to a narrative review published in October 2026 (OpenAlex W7222947771). The review, synthesizing data from seven primary clinical trials and additional systematic reviews, found that ketamine's effects typically emerge within hours but tend to dissipate within a week, returning symptoms to baseline. This transient benefit was most consistently observed with intravenous administration at 0.5 mg/kg, while other routes (such as intranasal or oral) yielded less reliable outcomes.

Mechanistic Insights: Glutamatergic Modulation and Neuroplasticity

Ketamine's rapid action in OCD is believed to stem from its antagonism of the N-methyl-D-aspartate (NMDA) receptor, a key component of glutamatergic neurotransmission. This mechanism is analogous to its established effects in treatment-resistant depression, where ketamine is thought to promote synaptic plasticity and neural circuit remodeling. The review notes that the acute reduction in obsessive-compulsive symptoms may reflect a temporary window of enhanced neuroplasticity, during which patients could be more responsive to behavioral interventions such as Exposure and Response Prevention (ERP) therapy. Notably, this neuroplasticity window is a non-obvious opportunity: some trials have begun pairing ketamine infusions with ERP sessions, hypothesizing that the combination may yield more durable benefits than either approach alone.

Policy and Research Implications: Experimental Status and Clinical Caution

Despite promising acute effects, ketamine remains an experimental intervention for OCD and should not supplant first-line treatments such as selective serotonin reuptake inhibitors (SSRIs) or cognitive-behavioral therapy (CBT). The review emphasizes that ketamine use should be limited to research protocols or highly specialized clinical settings. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and analogous bodies in Europe and Brazil, have not approved ketamine for OCD, and its off-label use is subject to institutional review and oversight. The review calls for further randomized controlled trials to clarify optimal dosing, maintenance strategies, and long-term safety, as well as to determine whether adjunctive use with psychotherapy can extend the duration of benefit.

Risks, Unknowns, and Practical Limitations

Ketamine's short-lived efficacy in OCD presents a significant limitation, as repeated dosing protocols for maintenance have not been established and may carry cumulative risks. Adverse effects observed in trials include transient dissociation, blood pressure elevation, and rare emergence of psychotic symptoms. Long-term safety data in OCD populations is lacking, and there are concerns about misuse or diversion, particularly outside of controlled research environments. The review also highlights a real-world failure mode: some clinics have prematurely marketed ketamine for OCD based on depression data, exposing patients to interventions without robust evidence or established safety protocols. This underscores the need for clear clinical guidelines and regulatory vigilance as research progresses.

Future Directions: Toward Evidence-Based Integration

Ongoing and future trials are expected to address key questions regarding maintenance dosing, optimal integration with behavioral therapies, and patient selection criteria. The review suggests that ketamine's most promising role may be as an adjunct to evidence-based psychotherapy, leveraging its neuroplasticity-enhancing effects to facilitate therapeutic learning. However, until larger, rigorously designed studies are completed, ketamine should remain a tool for research and specialist care rather than routine clinical practice. For clinicians, researchers, and policymakers, the challenge will be to balance innovation with caution, ensuring that advances in neurobiology translate into safe, effective, and equitable care for individuals with refractory OCD.

By Dr. Ana Luisa Ferreira, MD, PhDReviewed by Dr. Rafael Mendes, MD, on 2026-10-21. Research based on primary literature, including OpenAlex W7222947771 and direct clinical trial sources.